金融界10月31日消息,再鼎医药董事会审核委员会将于2024年11月12日审议并批准2024年截至9月30日的三个月和九个月期间的未经审核的季度业绩,并计划在同日在香港联交所网站和公司网站上发布。公司管理层计划在第三季度业绩公告发布后,于当地时间上午8:00 / 香港时间下午9:00举行现场业绩电话会议和网络直播,以讨论第三季度业绩并回答提问。以上数据未经审核。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.